Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Interest & Investment Income (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Interest & Investment Income for 7 consecutive years, with $10.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 2.64% to $10.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $43.7 million, a 10.92% decrease, with the full-year FY2025 number at $43.7 million, down 10.92% from a year prior.
  • Interest & Investment Income was $10.6 million for Q4 2025 at Beam Therapeutics, down from $10.9 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $14.2 million in Q2 2024 to a low of -$52000.0 in Q2 2021.
  • A 5-year average of $7.7 million and a median of $10.3 million in 2023 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: plummeted 120.8% in 2021, then soared 55255.56% in 2022.
  • Beam Therapeutics' Interest & Investment Income stood at $54000.0 in 2021, then skyrocketed by 13994.44% to $7.6 million in 2022, then surged by 58.51% to $12.1 million in 2023, then fell by 9.42% to $10.9 million in 2024, then fell by 2.64% to $10.6 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Interest & Investment Income are $10.6 million (Q4 2025), $10.9 million (Q3 2025), and $12.3 million (Q2 2025).